RhumbLine Advisers
RCEL icon

RhumbLine Advisers’s Avita Medical RCEL Stock Holding History

RhumbLine Advisers’s Portfolio RCEL Stock Details RCEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$98.6K Sell
26,645
-1,188
-4% -$4.99K ﹤0.01% 3415
2025
Q4 		$96K Sell
27,833
-10,497
-27% -$41.9K ﹤0.01% 3487
2025
Q3 		$196K Sell
38,330
-3,838
-9% -$20K ﹤0.01% 3228
2025
Q2 		$223K Buy
42,168
+3,393
+9% +$24.7K ﹤0.01% 3172
2025
Q1 		$316K Buy
38,775
+3,448
+10% +$32.2K ﹤0.01% 2855
2024
Q4 		$452K Buy
35,327
+939
+3% +$11.1K ﹤0.01% 2733
2024
Q3 		$369K Sell
34,388
-2,142
-6% -$20.1K ﹤0.01% 2908
2024
Q2 		$289K Buy
36,530
+4,463
+14% +$42.5K ﹤0.01% 3023
2024
Q1 		$514K Buy
32,067
+1,043
+3% +$16.9K ﹤0.01% 2657
2023
Q4 		$426K Sell
31,024
-101
-0.3% -$1.16K ﹤0.01% 2762
2023
Q3 		$455K Buy
31,125
+4,096
+15% +$69.3K ﹤0.01% 2666
2023
Q2 		$460K Buy
+27,029
New +$397K ﹤0.01% 2740
2022
Q2 		– Sell
-22,913
Closed -$194K – 3209
2022
Q1 		$194K Buy
22,913
+4,326
+23% +$39.9K ﹤0.01% 2763
2021
Q4 		$223K Sell
18,587
-420
-2% -$6.41K ﹤0.01% 2807
2021
Q3 		$337K Buy
19,007
+1,096
+6% +$20.7K ﹤0.01% 2717
2021
Q2 		$368K Buy
+17,911
New +$353K ﹤0.01% 2702

Other funds holding RCEL

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

RhumbLine Advisers's RCEL Position: Q1 2026 in Review

RhumbLine Advisers reduced its Avita Medical (RCEL) stake by 4.3% in Q1 2026, selling an estimated $4.99K and leaving 26,645 shares worth $98.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3415.

RhumbLine Advisers first reported a position in RCEL in Q2 2021 and has held it in 16 quarters since. The position peaked at $514K in Q1 2024. 79 funds tracked by Wall St. Rank hold RCEL as of Q1 2026.

  • RhumbLine Advisers held 26,645 shares of Avita Medical worth $98.6K as of Q1 2026.
  • RhumbLine Advisers sold 1,188 Avita Medical shares in Q1 2026, an estimated $4.99K.
  • Avita Medical made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3415 holding.
  • RhumbLine Advisers first reported a position in Avita Medical in Q2 2021 and has held it in 16 quarters since.
  • RhumbLine Advisers's Avita Medical position peaked at $514K in Q1 2024.
  • 79 funds tracked by Wall St. Rank held Avita Medical as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.